Concepts (242)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Urinary Bladder Neoplasms | 47 | 2023 | 2248 | 8.850 |
Why?
|
Cystectomy | 22 | 2022 | 686 | 6.340 |
Why?
|
Carcinoma, Transitional Cell | 5 | 2022 | 808 | 1.690 |
Why?
|
Urologic Neoplasms | 6 | 2021 | 318 | 1.550 |
Why?
|
Prostatectomy | 8 | 2023 | 1879 | 1.520 |
Why?
|
Urology | 4 | 2018 | 396 | 1.220 |
Why?
|
Urinary Bladder | 7 | 2023 | 1173 | 1.120 |
Why?
|
Penile Neoplasms | 5 | 2023 | 161 | 1.120 |
Why?
|
Postoperative Complications | 17 | 2023 | 15281 | 1.080 |
Why?
|
Health Care Costs | 5 | 2020 | 3207 | 0.990 |
Why?
|
Kidney Neoplasms | 7 | 2022 | 4260 | 0.900 |
Why?
|
Urologic Surgical Procedures | 5 | 2019 | 301 | 0.900 |
Why?
|
Ureteral Neoplasms | 2 | 2021 | 111 | 0.770 |
Why?
|
Muscle Neoplasms | 2 | 2019 | 139 | 0.750 |
Why?
|
Prostatic Neoplasms | 11 | 2023 | 11059 | 0.700 |
Why?
|
Medical Records | 2 | 2016 | 1412 | 0.700 |
Why?
|
Nephrectomy | 5 | 2022 | 1048 | 0.690 |
Why?
|
Guideline Adherence | 4 | 2021 | 2265 | 0.660 |
Why?
|
Kidney Pelvis | 1 | 2019 | 188 | 0.650 |
Why?
|
Information Seeking Behavior | 1 | 2018 | 113 | 0.590 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2021 | 627 | 0.590 |
Why?
|
Smoking Cessation | 3 | 2023 | 2071 | 0.580 |
Why?
|
Urologic Surgical Procedures, Male | 1 | 2016 | 75 | 0.560 |
Why?
|
Blood Transfusion | 2 | 2020 | 1301 | 0.550 |
Why?
|
Cost of Illness | 2 | 2017 | 1859 | 0.550 |
Why?
|
Neoplasm Invasiveness | 11 | 2021 | 3617 | 0.540 |
Why?
|
Patient-Centered Care | 5 | 2019 | 1438 | 0.520 |
Why?
|
Antibiotic Prophylaxis | 3 | 2017 | 638 | 0.520 |
Why?
|
Cyclophosphamide | 1 | 2021 | 2241 | 0.520 |
Why?
|
Neoplasm Staging | 13 | 2022 | 11036 | 0.510 |
Why?
|
Germ-Line Mutation | 1 | 2022 | 1787 | 0.490 |
Why?
|
Aftercare | 1 | 2020 | 870 | 0.460 |
Why?
|
Ambulatory Care Facilities | 1 | 2020 | 934 | 0.450 |
Why?
|
Retrospective Studies | 35 | 2023 | 77410 | 0.450 |
Why?
|
Muscles | 4 | 2022 | 1613 | 0.440 |
Why?
|
Pathology, Surgical | 1 | 2014 | 155 | 0.440 |
Why?
|
Anemia | 1 | 2022 | 1502 | 0.430 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 6 | 2021 | 11524 | 0.430 |
Why?
|
Health Literacy | 2 | 2016 | 414 | 0.430 |
Why?
|
Medically Underserved Area | 1 | 2014 | 252 | 0.400 |
Why?
|
Patients | 1 | 2018 | 899 | 0.400 |
Why?
|
Reoperation | 2 | 2019 | 4200 | 0.380 |
Why?
|
Carcinoma, Renal Cell | 2 | 2022 | 3142 | 0.370 |
Why?
|
Humans | 82 | 2023 | 743811 | 0.370 |
Why?
|
Occupational Exposure | 1 | 2021 | 1787 | 0.370 |
Why?
|
Physician's Role | 1 | 2017 | 942 | 0.370 |
Why?
|
Aged | 39 | 2023 | 163178 | 0.370 |
Why?
|
Male | 56 | 2023 | 349776 | 0.350 |
Why?
|
Venous Thromboembolism | 2 | 2019 | 1670 | 0.350 |
Why?
|
Smoking | 5 | 2023 | 8984 | 0.350 |
Why?
|
Population Surveillance | 1 | 2020 | 2614 | 0.330 |
Why?
|
Androgen Antagonists | 1 | 2017 | 1376 | 0.330 |
Why?
|
Prostate-Specific Antigen | 1 | 2018 | 2471 | 0.320 |
Why?
|
Disease Management | 2 | 2019 | 2459 | 0.310 |
Why?
|
Chemotherapy, Adjuvant | 5 | 2021 | 3480 | 0.300 |
Why?
|
Databases, Factual | 8 | 2020 | 7729 | 0.290 |
Why?
|
Anti-Infective Agents | 1 | 2014 | 971 | 0.290 |
Why?
|
Middle Aged | 37 | 2023 | 213241 | 0.290 |
Why?
|
Physician-Patient Relations | 2 | 2017 | 3229 | 0.290 |
Why?
|
BCG Vaccine | 4 | 2023 | 369 | 0.280 |
Why?
|
Biomedical Research | 2 | 2021 | 3308 | 0.280 |
Why?
|
Internet | 1 | 2018 | 3058 | 0.270 |
Why?
|
Patient Education as Topic | 1 | 2016 | 2278 | 0.270 |
Why?
|
Neoplasms, Radiation-Induced | 2 | 2021 | 547 | 0.270 |
Why?
|
Hospital Costs | 3 | 2022 | 985 | 0.260 |
Why?
|
Cancer Care Facilities | 2 | 2020 | 402 | 0.260 |
Why?
|
Anticoagulants | 2 | 2023 | 4599 | 0.260 |
Why?
|
Risk Factors | 12 | 2021 | 72252 | 0.260 |
Why?
|
Patient Readmission | 3 | 2017 | 3117 | 0.250 |
Why?
|
Female | 39 | 2023 | 380020 | 0.250 |
Why?
|
Neoadjuvant Therapy | 4 | 2021 | 2727 | 0.250 |
Why?
|
Carcinoma | 1 | 2016 | 2375 | 0.250 |
Why?
|
Health Services Accessibility | 3 | 2019 | 5136 | 0.240 |
Why?
|
Vinblastine | 2 | 2021 | 501 | 0.220 |
Why?
|
Environmental Exposure | 1 | 2017 | 4232 | 0.220 |
Why?
|
Survival Rate | 8 | 2021 | 12786 | 0.210 |
Why?
|
Incidence | 7 | 2023 | 20948 | 0.210 |
Why?
|
Comorbidity | 5 | 2021 | 10380 | 0.210 |
Why?
|
Adjuvants, Immunologic | 3 | 2023 | 999 | 0.200 |
Why?
|
Communication | 2 | 2017 | 3748 | 0.200 |
Why?
|
Lower Gastrointestinal Tract | 1 | 2020 | 14 | 0.190 |
Why?
|
Deoxycytidine | 2 | 2021 | 826 | 0.180 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2023 | 4033 | 0.180 |
Why?
|
Ileus | 1 | 2020 | 58 | 0.180 |
Why?
|
Length of Stay | 5 | 2021 | 6311 | 0.180 |
Why?
|
Practice Guidelines as Topic | 4 | 2021 | 7270 | 0.170 |
Why?
|
Obesity | 2 | 2020 | 12744 | 0.160 |
Why?
|
Histological Techniques | 1 | 2019 | 198 | 0.160 |
Why?
|
Survival Analysis | 4 | 2021 | 10251 | 0.160 |
Why?
|
Episode of Care | 1 | 2019 | 126 | 0.160 |
Why?
|
Germ Cells | 1 | 2022 | 629 | 0.160 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2023 | 501 | 0.160 |
Why?
|
Combined Modality Therapy | 3 | 2019 | 8637 | 0.160 |
Why?
|
Cisplatin | 2 | 2021 | 1662 | 0.160 |
Why?
|
Biopsy | 3 | 2019 | 6750 | 0.160 |
Why?
|
Surgical Procedures, Operative | 2 | 2021 | 1877 | 0.160 |
Why?
|
Defoliants, Chemical | 1 | 2017 | 6 | 0.160 |
Why?
|
Doxorubicin | 2 | 2021 | 2234 | 0.150 |
Why?
|
Medical Oncology | 2 | 2021 | 2267 | 0.150 |
Why?
|
Methotrexate | 2 | 2021 | 1726 | 0.150 |
Why?
|
Age Factors | 6 | 2021 | 18355 | 0.150 |
Why?
|
Treatment Outcome | 13 | 2021 | 63042 | 0.150 |
Why?
|
Aged, 80 and over | 13 | 2023 | 57744 | 0.150 |
Why?
|
Washington | 2 | 2017 | 314 | 0.150 |
Why?
|
Vietnam Conflict | 1 | 2017 | 99 | 0.150 |
Why?
|
Testicular Neoplasms | 1 | 2023 | 803 | 0.150 |
Why?
|
Hospital Charges | 1 | 2019 | 362 | 0.150 |
Why?
|
Prognosis | 6 | 2022 | 29052 | 0.150 |
Why?
|
United States | 14 | 2023 | 69859 | 0.140 |
Why?
|
Prostate | 2 | 2022 | 1763 | 0.140 |
Why?
|
Cystoscopy | 2 | 2014 | 133 | 0.140 |
Why?
|
Lymph Nodes | 2 | 2018 | 3476 | 0.140 |
Why?
|
Surgical Wound Dehiscence | 1 | 2017 | 214 | 0.140 |
Why?
|
Hospital Mortality | 3 | 2019 | 5316 | 0.140 |
Why?
|
Risk Assessment | 5 | 2021 | 23327 | 0.140 |
Why?
|
Research Report | 1 | 2019 | 355 | 0.140 |
Why?
|
Lymphatic Metastasis | 3 | 2018 | 2924 | 0.130 |
Why?
|
SEER Program | 4 | 2023 | 1507 | 0.130 |
Why?
|
Watchful Waiting | 1 | 2019 | 491 | 0.130 |
Why?
|
Carcinoma in Situ | 1 | 2020 | 805 | 0.120 |
Why?
|
Hospitals | 2 | 2019 | 3953 | 0.120 |
Why?
|
Insurance, Health | 2 | 2019 | 2492 | 0.120 |
Why?
|
Registries | 3 | 2019 | 8090 | 0.120 |
Why?
|
Multivariate Analysis | 4 | 2019 | 12243 | 0.120 |
Why?
|
Kaplan-Meier Estimate | 3 | 2021 | 6539 | 0.120 |
Why?
|
Patient Transfer | 2 | 2017 | 762 | 0.110 |
Why?
|
Truth Disclosure | 1 | 2017 | 436 | 0.110 |
Why?
|
Transurethral Resection of Prostate | 1 | 2014 | 83 | 0.110 |
Why?
|
Cost-Benefit Analysis | 3 | 2020 | 5388 | 0.110 |
Why?
|
Lymph Node Excision | 4 | 2023 | 1262 | 0.110 |
Why?
|
Delivery of Health Care | 2 | 2021 | 5319 | 0.110 |
Why?
|
Mortality | 3 | 2019 | 2862 | 0.110 |
Why?
|
Hospitals, Teaching | 1 | 2017 | 1180 | 0.110 |
Why?
|
Circumcision, Male | 1 | 2014 | 150 | 0.110 |
Why?
|
Radiotherapy | 1 | 2019 | 1533 | 0.100 |
Why?
|
Piperidines | 1 | 2020 | 1601 | 0.100 |
Why?
|
Quality of Health Care | 2 | 2019 | 4370 | 0.100 |
Why?
|
Laparoscopy | 1 | 2023 | 2148 | 0.100 |
Why?
|
Health Maintenance Organizations | 1 | 2014 | 642 | 0.100 |
Why?
|
Regression Analysis | 1 | 2020 | 6457 | 0.090 |
Why?
|
Medicare | 3 | 2020 | 6565 | 0.090 |
Why?
|
Workplace | 1 | 2017 | 836 | 0.090 |
Why?
|
Cystotomy | 1 | 2010 | 3 | 0.090 |
Why?
|
Urinary Bladder Calculi | 1 | 2010 | 12 | 0.090 |
Why?
|
Tumor Burden | 1 | 2016 | 1917 | 0.090 |
Why?
|
Patient Preference | 1 | 2017 | 889 | 0.090 |
Why?
|
Neoplasm Metastasis | 2 | 2021 | 4848 | 0.090 |
Why?
|
Research | 1 | 2018 | 1999 | 0.090 |
Why?
|
Cohort Studies | 3 | 2023 | 40545 | 0.090 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2023 | 9239 | 0.090 |
Why?
|
Rectal Neoplasms | 1 | 2018 | 1205 | 0.080 |
Why?
|
Lithotripsy | 1 | 2010 | 142 | 0.080 |
Why?
|
Gastrointestinal Diseases | 1 | 2017 | 1171 | 0.080 |
Why?
|
Genomics | 2 | 2022 | 5714 | 0.080 |
Why?
|
Logistic Models | 4 | 2019 | 13404 | 0.080 |
Why?
|
Hypocalcemia | 1 | 2010 | 191 | 0.080 |
Why?
|
Adult | 13 | 2023 | 213889 | 0.080 |
Why?
|
Military Personnel | 1 | 2017 | 1133 | 0.080 |
Why?
|
Proportional Hazards Models | 5 | 2021 | 12354 | 0.080 |
Why?
|
Environmental Pollutants | 1 | 2017 | 1179 | 0.080 |
Why?
|
Lung Diseases | 1 | 2017 | 1887 | 0.070 |
Why?
|
Delirium | 1 | 2018 | 1611 | 0.070 |
Why?
|
Pilot Projects | 2 | 2016 | 8316 | 0.070 |
Why?
|
Equipment Design | 1 | 2014 | 3574 | 0.070 |
Why?
|
Cell Differentiation | 1 | 2022 | 11478 | 0.060 |
Why?
|
Thyroidectomy | 1 | 2010 | 879 | 0.060 |
Why?
|
Skin Neoplasms | 1 | 2023 | 5691 | 0.060 |
Why?
|
Administration, Intravesical | 1 | 2023 | 91 | 0.060 |
Why?
|
Veterans | 1 | 2017 | 2519 | 0.060 |
Why?
|
Neoplasms | 2 | 2023 | 21675 | 0.060 |
Why?
|
Health Personnel | 1 | 2017 | 3217 | 0.060 |
Why?
|
Retroperitoneal Space | 1 | 2023 | 176 | 0.060 |
Why?
|
Parathyroid Hormone | 1 | 2010 | 1800 | 0.060 |
Why?
|
Attitude of Health Personnel | 1 | 2017 | 3839 | 0.050 |
Why?
|
Hospitalization | 2 | 2020 | 10259 | 0.050 |
Why?
|
Socioeconomic Factors | 1 | 2016 | 7784 | 0.050 |
Why?
|
Time Factors | 2 | 2021 | 40038 | 0.050 |
Why?
|
Physicians | 1 | 2020 | 4569 | 0.050 |
Why?
|
Adenocarcinoma | 1 | 2019 | 6363 | 0.050 |
Why?
|
Odds Ratio | 1 | 2014 | 9848 | 0.050 |
Why?
|
Referral and Consultation | 1 | 2014 | 3530 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 1 | 2022 | 17439 | 0.050 |
Why?
|
Perioperative Period | 1 | 2021 | 256 | 0.040 |
Why?
|
Follow-Up Studies | 5 | 2018 | 39001 | 0.040 |
Why?
|
Ambulatory Surgical Procedures | 1 | 2023 | 455 | 0.040 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2013 | 5170 | 0.040 |
Why?
|
Anti-Bacterial Agents | 1 | 2017 | 7172 | 0.040 |
Why?
|
Young Adult | 3 | 2019 | 56392 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2023 | 13112 | 0.040 |
Why?
|
Calibration | 1 | 2020 | 816 | 0.040 |
Why?
|
Cross-Sectional Studies | 3 | 2023 | 25032 | 0.040 |
Why?
|
Quality of Life | 2 | 2018 | 12788 | 0.040 |
Why?
|
Muscle, Smooth | 1 | 2021 | 934 | 0.040 |
Why?
|
Evaluation Studies as Topic | 1 | 2019 | 1677 | 0.040 |
Why?
|
Calcium | 1 | 2010 | 5755 | 0.040 |
Why?
|
Adolescent | 3 | 2019 | 85729 | 0.040 |
Why?
|
Penis | 1 | 2017 | 214 | 0.040 |
Why?
|
Area Under Curve | 1 | 2020 | 1654 | 0.030 |
Why?
|
Sex Factors | 2 | 2020 | 10394 | 0.030 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2019 | 397 | 0.030 |
Why?
|
Internationality | 1 | 2021 | 1002 | 0.030 |
Why?
|
Gastrointestinal Agents | 1 | 2020 | 494 | 0.030 |
Why?
|
Probability | 1 | 2020 | 2505 | 0.030 |
Why?
|
Treatment Failure | 1 | 2020 | 2617 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2020 | 15142 | 0.030 |
Why?
|
Fee-for-Service Plans | 1 | 2020 | 694 | 0.030 |
Why?
|
Professional Role | 1 | 2017 | 306 | 0.030 |
Why?
|
Medically Uninsured | 1 | 2019 | 853 | 0.030 |
Why?
|
Comparative Effectiveness Research | 1 | 2018 | 680 | 0.030 |
Why?
|
Personality | 1 | 2017 | 552 | 0.030 |
Why?
|
Job Satisfaction | 1 | 2017 | 535 | 0.030 |
Why?
|
ROC Curve | 1 | 2020 | 3527 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2017 | 1770 | 0.030 |
Why?
|
Prospective Studies | 3 | 2023 | 53250 | 0.020 |
Why?
|
Social Behavior | 1 | 2017 | 1126 | 0.020 |
Why?
|
Recovery of Function | 1 | 2020 | 2922 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2017 | 1503 | 0.020 |
Why?
|
Algorithms | 1 | 2010 | 13869 | 0.020 |
Why?
|
Interpersonal Relations | 1 | 2017 | 1424 | 0.020 |
Why?
|
Urinary Bladder, Neurogenic | 1 | 2010 | 165 | 0.020 |
Why?
|
Social Support | 1 | 2017 | 2118 | 0.020 |
Why?
|
Health Expenditures | 1 | 2020 | 2348 | 0.020 |
Why?
|
Kidney | 1 | 2022 | 7185 | 0.020 |
Why?
|
Risk | 1 | 2019 | 9677 | 0.020 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2020 | 2200 | 0.020 |
Why?
|
Medicaid | 1 | 2019 | 2736 | 0.020 |
Why?
|
California | 1 | 2010 | 1402 | 0.020 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 3047 | 0.020 |
Why?
|
Catheterization | 1 | 2010 | 1469 | 0.020 |
Why?
|
Healthcare Disparities | 1 | 2019 | 3155 | 0.010 |
Why?
|
Inpatients | 1 | 2015 | 2515 | 0.010 |
Why?
|
Health Status | 1 | 2017 | 4031 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8385 | 0.010 |
Why?
|
Patient Discharge | 1 | 2015 | 3317 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2021 | 19894 | 0.010 |
Why?
|
Mental Health | 1 | 2017 | 3012 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2020 | 5752 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2016 | 15067 | 0.010 |
Why?
|
Pregnancy | 1 | 2019 | 29140 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2014 | 9944 | 0.010 |
Why?
|
Infant | 1 | 2010 | 35122 | 0.000 |
Why?
|
Child, Preschool | 1 | 2010 | 40964 | 0.000 |
Why?
|
Concepts
(242)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(61)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_